AstraZeneca PLC (LON:AZN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 195.93B +9.9% |
| Revenue (ttm) | 46.25B +8.6% |
| Net Income | 7.87B +25.9% |
| EPS | 5.03 +25.8% |
| Shares Out | 1.55B |
| PE Ratio | 25.09 |
| Forward PE | 15.66 |
| Dividend | 2.39 (1.89%) |
| Ex-Dividend Date | Aug 6, 2026 |
| Volume | 3,629,220 |
| Open | 11,818 |
| Previous Close | 12,632 |
| Day's Range | 11,702 - 12,080 |
| 52-Week Range | 10,524 - 15,732 |
| Beta | 0.22 |
| Analysts | Buy |
| Price Target | 15,749.19 (+33.24%) |
| Earnings Date | Jul 27, 2026 |
About AstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Topr... [Read more]
Financial Performance
In 2025, AstraZeneca's revenue was $58.74 billion, an increase of 8.63% compared to the previous year's $54.07 billion. Earnings were $10.23 billion, an increase of 45.34%.
Financial numbers in USD Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for AZN stock is "Buy." The 12-month stock price target is 15,749p, which is an increase of 33.24% from the latest price.
News
5 Things to Know Before the Stock Market Opens on Monday
Stock futures are pointing to a higher open to kick off August trading as investors look ahead to a packed week of earnings reports; oil prices are tumbling after the U.S. paused strikes on Iran over ...
Citi views report of AstraZeneca, Bristol Myers talks as surprising
Citi analyst Graham Parry is surprised by the Financial Times report of a potential merger between AstraZeneca (AZN) and Bristol Myers (BMY). The firm believes Astra’s pipeline is “best-in-sector” and...
AstraZeneca tie-up talks with Bristol-Myers Squibb are moving stocks. Analysts are puzzled.
AstraZeneca shares were slumping while Bristol-Myers Squibb was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the...
Bristol Myers Squibb Stock Soars on Report of $400 Billion Merger Talks With AstraZeneca
The merger would be one of the biggest pharma deals ever. AstraZeneca's market capitalization stood at $264 billion as of Friday's close, while Bristol Myers Squibb had a total valuation of $133 billi...
AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb
AstraZeneca (AZN) Stock Plummets Amid Merger Talks with Bristol-Myers Squibb
AstraZeneca Weighs a Deal Its CEO Said It Didn't Need
AstraZeneca Weighs a Deal Its CEO Said It Didn't Need
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger
AstraZeneca and Bristol Myers Squibb Explore $400 Billion Merger
AstraZeneca drops 6% to $159.98 after report of Bristol Myers merger talks
05:01 EDT AstraZeneca (AZN) drops 6% to $159.98 after report of Bristol Myers (BMY) merger talks
Bristol Myers jumps 8% to $70.47 after report of AstraZeneca merger talks
05:02 EDT Bristol Myers (BMY) jumps 8% to $70.47 after report of AstraZeneca (AZN) merger talks
AstraZeneca in talks over potential Bristol-Myers Squibb megadeal that would create world’s biggest drugmaker
Why did AstraZeneca shares fall 6% after Bristol Myers Squibb merger reports?
AstraZeneca shares fell more than 6% in early trading on Monday after reports emerged that the British pharmaceutical giant had held preliminary discussions with US-based Bristol Myers Squibb over a p...
AstraZeneca Shares Drop After Reports of Bristol Myers Squibb Merger Talks
If maintained until close, the decline would be the stock's biggest one-day percentage fall since the day of the 2024 U.S. presidential election.
AstraZeneca shares drop 7% after report on $400 billion merger talks with Bristol Myers Squibb
AstraZeneca is reportedly in talks with U.S. peer Bristol Myers Squibb over a megadeal. If completed, a combined company could be valued at roughly roughly $400 billion.
AstraZeneca holds talks with Bristol Myers Squibb over £300bn merger
A deal by AstraZeneca chief executive Sir Pascal Soriot would extend the drugmaker's footprint in the US market.
AstraZeneca shares tumble 7% after reported Bristol Myers talks
AstraZeneca shares tumbled 7% in early trading on Monday following reports of talks between the European pharmaceutical giant and U.S.-based Bristol Myers Squibb , baffling investors and analysts.
AstraZeneca holds talks with Bristol Myers Squibb on $400bn merger
Tie-up would be one of the biggest pharmaceutical deals ever and create the world’s fourth-largest drugmaker Business live – latest updates Britain’s biggest drugmaker AstraZeneca is in discussions to...
AstraZeneca, Bristol Myers Squibb Hold Early Merger Talks for Potential $400B Deal
British drug giant AstraZeneca ($AZN) and U.S.-based Bristol Myers Squibb ($BMY) have held talks about a potential merger that could create one of the world’s largest pharmaceutical companies. Accordi...
AstraZeneca And Bristol Myers Reportedly In Talks On $400 Bln Deal
(RTTNews) - AstraZeneca Plc (AZN) and Bristol Myers Squibb (BMY) are in talks over a $400 billion deal to combine the companies, Financial Times reported.
AstraZeneca and Bristol-Myers Squibb Explore Potential Merger
AstraZeneca and Bristol-Myers Squibb Explore Potential Merger
AZN Looks 5.5% Undervalued on GF Value⢠Amid $400B Merger Talks
AZN Looks 5.5% Undervalued on GF Value⢠Amid $400B Merger Talks
AstraZeneca Considers Merger with Bristol-Myers Squibb, Valued at $400 Billion
AstraZeneca Considers Merger with Bristol-Myers Squibb, Valued at $400 Billion
AstraZeneca in discussions to combine with Bristol Myers for $400B, FT says
AstraZeneca (AZN) is in discussions to combine with Bristol Myers Squibb (BMY) in a deal valued at nearly $400B, Oliver Barnes, James Fontanella-Khan, Aaron Kirchfeld, and Arash Massoudi of The…
AstraZeneca holds talks with Bristol Myers Squibb on $400B megadeal: report
The deal could create one of the world's biggest pharmaceutical groups with a combined value of nearly $400 billion.
AZN Looks 5.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AZN Looks 5.5% Undervalued on GF Value⢠Amid Strong Dividend Profile
AstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
UK pharmaceutical company AstraZeneca is considering a deal to merge with its U.S. competitor Bristol Myers Squibb, according to a report by the Financial Times. The megadeal would be one of the large...